Synlogic to Merge with Caldera Therapeutics in $278M Private Placement Deal
Synlogic (OTCQB:SYBX) has announced a merger agreement with privately held biotech company Caldera Therapeutics, creating a new publicly traded entity focused on advancing CLD-423, an experimental bispecific antibody for inflammatory bowel disease. The all-stock transaction will be accompanied by a $278 million private placement to fund development through Phase 2 trials and support operations until at least 2029. The combined company plans to list under the ticker symbol CALD on Nasdaq following regulatory approvals expected in early 2027. CLD-423 is currently undergoing a Phase 1 trial with promising preliminary results, including favorable tolerability and long serum half-life. Existing Synlogic shareholders will own approximately 2.3% of the new entity post-merger. The deal represents a strategic shift for Synlogic from its prior development focus to supporting Caldera’s pipeline. While the financing reduces near-term capital risks, current investors face significant dilution as ownership is largely transferred to Caldera and private placement participants.
Topics: biotech inflammatory bowel disease (IBD) private placement stock merger